These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56. [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease]. Reinders MG; Terra JB; Reyners AK; Aarts MJ; de Haas ER; Mosterd K Ned Tijdschr Geneeskd; 2016; 160():D187. PubMed ID: 28000572 [TBL] [Abstract][Full Text] [Related]
57. Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma. Amin SH; Motamedi KK; Ochsner MC; Song TE; Hybarger CP Discov Med; 2013 Nov; 16(89):229-32. PubMed ID: 24229739 [TBL] [Abstract][Full Text] [Related]
58. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned. Soon SL; Ibrahim SF; Arron ST Br J Dermatol; 2019 Jul; 181(1):208-209. PubMed ID: 30628055 [No Abstract] [Full Text] [Related]
59. Multiple Lesions in Irradiated Skin. Wetzel M; Jung JY; Brown TS JAMA Oncol; 2019 May; 5(5):728-729. PubMed ID: 30653217 [No Abstract] [Full Text] [Related]
60. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]